Prasinezumab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Prasinezumab
- humanized igg1 kappa anti alpha synuclein antibody
- HUMANIZED IGG1, KAPPA ANTI-ALPHA-SYNUCLEIN ANTIBODY
- prasinezumab
- Prasinezumab
- prasinezumab [INN]
- PRASINEZUMAB [USAN]
- Prasinezumab [WHO-DD]
- prasinezumab inn
- prasinezumab usan
- prasinezumab who dd
- prx 002
- Prx-002
- prx002
- Prx002
- PRX002
- rg 7935
- RG-7935
- rg7935
- RG7935
- ro 7046015
- RO-7046015
- ro7046015
- Ro7046015
- RO7046015
- CAS registry numbers
- 1960462-19-4
- ChEMBL ID
- CHEMBL4298077
- FDA ingredient codes (UNII)
- P3Z0Z3P1ZI
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- prasinezumab
- Type
- Antibody
- Drug name stem
- -mab; -mab
- Mechanism
- Alpha-synuclein binding agent
- Action type
- BINDING_AGENT
- Target
- Alpha-synuclein
- Protein identifier
- P37840
- Action
- Binding
- Action type
- Binding
- Target
- synuclein alpha
- Gene symbol
- SNCA
- Protein identifier
- P37840
- Median affinity
- 10.32
- Affinity units
- pKd
- Action
- Binding
- Action type
- Binding
- Target
- synuclein alpha
- Gene symbol
- SNCA
- Protein identifier
- P37840
- Median affinity
- 7.7
- Affinity units
- pKd
Open Targets mechanisms
- Mechanism
- Alpha-synuclein binding agent
- Action type
- BINDING AGENT
- Target
- Alpha-synuclein
Investigated indications
- Condition
- Parkinson Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition identifier
- HP_0001268
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 3
- NCT02095171
- NCT02157714
- NCT03100149
- NCT04777331
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVAS50ISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGG100AGIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Glycosylation sites (N)
- Sequence
- Asn-296 $ Asn-296''''
- Component
- Disulfide bridge location
- Sequence
- 22-96 $ 22''-96'' $ 23'-94' $ 23'''-94''' $ 140'-200' $ 140'''-200''' $ 143-199 $ 143''-199'' $ 219-220' $ 219''-220''' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-296 $ Asn-296''
Related records
Trials (6)
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
- Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
- Prevent Cognitive Decline in GBA-associated Parkinson's Disease
- Single Ascending Dose Study of PRX002 in Healthy Subjects
In development for (1)
- Parkinson disease Phase 2
Targets (1)
- SNCA Alpha-synuclein binding agent